CTRI/2009/091/000655已完成3 期
Prospective, multicentre, open label, clinical study to evaluate efficacy and safety of R-TPR-011 in patients with multiple sclerosis.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosis of relapsing remitting multiple sclerosis based upon McDonald criteria at the time of entry
- •Subject having atleast 2 exacerbations in the 2 years prior to but stable for atleast 4 weeks before study entry
- •Subject with EDSS <=5.0
- •Women of child bearing potential having a negative pregnancy test and taking adequate birth control measures/documented to be postmenopausal
- •1.Able to comprehend and give informed consent for the study and willing to come for follow up visit as per protocol requirement
- •2.Consent from Legally Acceptable Representative (LAR), if subject is not in the condition to give consent. However, when the subject is stable and is able to give consent, consent would be obtained on a separate ICF to confirm his/her willingness to continue in the study.
排除标准
- •1.Diagnosis of primary and/or secondary progressive MS.
- •(Primary progressive MS: Patients that develop a sustained deterioration of their neurological function from the beginning,
- •Secondary progressive MS: Patients with relapsing remitting MS eventually develop sustained deterioration with or without relapses superimposed).
- •2.Patients with h/o and/or current severe depression and/or suicidal ideation.
- •3.Patients on steroids for treatment of MS within preceding 4 weeks.
- •4.History of any significant cardiac, hepatic, pulmonary, or renal disease; immune deficiency; and/or other medical conditions that would preclude therapy with interferon beta.
- •5.Patients with Serum creatinine 1.5 x ULN.
- •6.History of severe allergic and/or anaphylactic reactions and/or history of hypersensitivity to human albumin
- •7.History of seizures within the 3 months prior to starting this study.
- •8.History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen or other NSAIDs that would preclude use of atleast one of these during the study.
- •9.History of intolerance and/or hypersensitivity to interferons and/or to any of the excipients.
- •10.Previous use of interferon beta within 1 week prior to enrolment.
- •11.Subjects positive for HIV, HBsAg or HCV.
- •12.Subject participation in another clinical trial 30 days prior to administration of IP.
- •13.Pregnant and lactating females.
- •14.Any other condition which investigator feels would pose a significant hazard to subject if IP is administered.
研究者
相似试验
已完成
3 期
A clinical trial to study the effect of R-TPR-020 in patients undergoing treatment for infertility.CTRI/2009/091/000888Reliance Life Sciences Pvt Ltd45
已完成
3 期
A clinical trial to study the effect of R-TPR013 in patients undergoing treatment for infertilityCTRI/2010/091/001063Reliance Life Sciences Pvt Ltd102
已完成
4 期
Amla capsules in improving Overall healthCTRI/2022/09/045192Vestige Marketing Pvt Ltd50
已完成
4 期
clinical trail to evaluate efficacy and safety of Vestige Noni capsules in improving Overall health of healthy population.CTRI/2022/09/045314Vestige Marketing Pvt Ltd50
已完成
4 期
Assessment of efficacy and safety of Lipid based Amphotericin B gel 0.1% (Amfy gel®) in patients with moderate to severe vulvovaginal candidiasisCTRI/2014/02/004409Intas Pharmaceuticals Ltd60